Incyte (INCY) Q1 2025 10-Q Quarterly Report
Filed: Apr 29, 2025Period ending Mar 31, 2025
Industrials
Services-Commercial Physical & Biological ResearchSEC EDGAR Incyte (INCY) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on Apr 29, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Incyte Q1 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenues $1,052.9M, up 19.5% YoY from $880.9M; JAKAFI $709.4M (+24.1%), OPZELURA $118.7M (+38.6%)
- • Net income $158.2M, down 6.6% YoY from $169.5M; basic EPS $0.82 vs $0.76 YoY; operating margin affected by cost increases
- • Best segment: JAKAFI revenues $709.4M (+$137.6M), driven by 10% volume growth; worst: ICLUSIG declined slightly to $29.5M from $30.3M
- • Operating cash flow $266.1M, up from $218.8M YoY; cash, equivalents, securities $2.4B at quarter-end; minimal investing and stable financing outflows
- • Management cautious: ongoing litigation risk for OPZELURA rebates; expects sales allowances to fluctuate, impacts from inflation and government reimbursements
Incyte Q1 2025 Quarterly FinancialsXBRL
Revenue
$1.1B
▲ +19.5% YoY
Net Income
$158M
▼ -6.7% YoY
Operating Margin
19.5%
▲ +905bp YoY
Net Margin
15.0%
▼ -422bp YoY
EPS (Diluted)
$0.80
▲ +6.7% YoY
Operating Cash Flow
$266M
▲ +21.6% YoY
Source: XBRL data from Incyte Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Incyte Quarterly Reports
Get deeper insights on Incyte
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.